36057-46-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-3-Methoxy-Pyridine2-Carbonitrile is used as a building block in organic synthesis for the development of biologically active molecules. Its unique structure and reactivity contribute to the synthesis of complex molecules with potential applications in medicinal chemistry, aiding in the creation of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-3-Methoxy-Pyridine2-Carbonitrile serves as a precursor for the synthesis of various compounds with pesticidal properties. Its role in the development of agrochemicals helps in enhancing crop protection and improving agricultural productivity by combating pests and diseases.

InChI:InChI=1/C7H5BrN2O/c1-11-7-2-5(8)4-10-6(7)3-9/h2,4H,1H3

Upstream product

• 886373-28-0 5-bromo-3-fluoropyridine-2-carbonitrile 
• 124-41-4 sodium methylate 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 67-56-1 methanol 

Downstream Products

• 1615720-26-7 C₁₉H₁₄N₄O₄S 
• 1615720-27-8 C₁₉H₁₄N₄O₄S 
• 1208072-08-5 C₁₉H₁₆N₄O₃S 
• 1208072-09-6 C₁₉H₁₆N₄O₃S 
• 1208072-02-9 C₁₉H₁₆N₄O₂S 
• 1208072-96-1 C₂₄H₁₉N₅O₂S 
• 1208071-77-5 C₁₈H₁₄N₄O₂S 
• 1208072-80-3 C₁₇H₁₁N₃O₃S 

Relevant academic research and scientific papers

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF

The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7 straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7alkyl, halo C1-C7 alkyl and the like. The present invention also relates to a method for preparing the compound, pharmaceutical compositions comprising the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES

The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were

Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were

INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS

Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.